WO2016044701A1 - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use Download PDF

Info

Publication number
WO2016044701A1
WO2016044701A1 PCT/US2015/050889 US2015050889W WO2016044701A1 WO 2016044701 A1 WO2016044701 A1 WO 2016044701A1 US 2015050889 W US2015050889 W US 2015050889W WO 2016044701 A1 WO2016044701 A1 WO 2016044701A1
Authority
WO
WIPO (PCT)
Prior art keywords
abiraterone acetate
unit dosage
less
dose
composition
Prior art date
Application number
PCT/US2015/050889
Other languages
English (en)
French (fr)
Inventor
Maura Murphy
Paul NEMETH
H. William Bosch
Matthew CALLAHAN
Satya Bhamidipati
Jason Coleman
Christopher Hill
Original Assignee
Iceutica Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016044701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Priority to CN201580050453.8A priority Critical patent/CN106687112A/zh
Priority to CA2958316A priority patent/CA2958316A1/en
Priority to TNP/2018/000318A priority patent/TN2018000318A1/en
Priority to AP2017009804A priority patent/AP2017009804A0/en
Priority to KR1020177008938A priority patent/KR102491439B1/ko
Priority to BR112017003219A priority patent/BR112017003219A2/pt
Priority to KR1020237001893A priority patent/KR102617537B1/ko
Priority to MA40116A priority patent/MA40116A1/fr
Application filed by Iceutica Inc. filed Critical Iceutica Inc.
Priority to TN2017000098A priority patent/TN2017000098A1/en
Priority to SG11201701139YA priority patent/SG11201701139YA/en
Priority to EP15842591.8A priority patent/EP3193857A4/en
Priority to JP2017512783A priority patent/JP2017528457A/ja
Priority to MX2017003525A priority patent/MX2017003525A/es
Priority to AU2015317466A priority patent/AU2015317466A1/en
Priority to EA201790650A priority patent/EA201790650A1/ru
Priority to MDA20170048A priority patent/MD20170048A2/ro
Publication of WO2016044701A1 publication Critical patent/WO2016044701A1/en
Priority to IL250270A priority patent/IL250270B/en
Priority to PH12017500239A priority patent/PH12017500239A1/en
Priority to CONC2017/0002472A priority patent/CO2017002472A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Abiraterone ((3 )-17-(pyridin-3-yl) androsta-5, 16-dien-3-ol; CAS #: 154229-19-3; Formula: C24H31NO; Mol. Weight: 349.5 g/mol) is an inhibitor of CYP17 and thus interferes with the synthesis of androgens in the testes, adrenal glands and prostate tumor tissue.
  • Abiraterone acetate (17-(3-Pyridyl) androsta-5, acetate; CAS #154229-18-2), a prodrug of abiraterone, is approved in the United States for treatment of castration-resistant prostate cancer. Abiraterone acetate is considered poorly water soluble.
  • Zytiga® Tablets (250 mg; National Drug Code Number 57894-150; NDA 202379) are approved in the United States in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
  • the prescribing information for Zytiga® tablets recommends 1,000 mg (4 x 250 mg tablets) administered orally once daily in combination with prednisone (5 mg) administered orally twice daily.
  • the European approval of Zytiga® is for administration in combination with either prednisone or prednisolone.
  • Prescribing information for Zytiga® states that it must be taken on an empty stomach and that no food should be consumed for at least two hours before the dose is taken and for and for at least one hour after the dose is taken.
  • the prescribing information explains that at a dose of 1,000 mg daily in patients with metastatic, castration resistant prostate cancer the steady-state values (mean ⁇ SD) of Cmax were 226 ⁇ 178 ng/mL and of AUC were 1173 ⁇ 690 ng.hr/mL.
  • abiraterone Cmax and AUC 0 - ⁇ were approximately 7- and 5-fold higher, respectively, when Zytiga® was administered with a low- fat meal (7% fat, 300 calories) compared to administration in the fasted state.
  • Abiraterone Cmax and AUC o- ⁇ were approximately 17- and 10-fold higher, respectively, when Zytiga® was administered with a high-fat (57% fat, 825 calories) meal compared to administration in the fasted state.
  • compositions including unit dosage forms, comprising abiraterone acetate as well as methods for producing and using such compositions. Described herein is unit dosage form of abiraterone acetate, wherein a 500mg dose of the unit dosage form is bioequivalent to a lOOOmg dose of Zytiga® in healthy male subjects in the fasted state.
  • a unit dosage form of abiraterone acetate wherein the ratio of the log of the geometric mean of the AUC(o- ⁇ ) for a 500mg dose administered to healthy male subjects in the fasted state compared to a lOOOmg dose of Zytiga® administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1;
  • a unit dosage form of abiraterone acetate, wherein the ratio of the log of the geometric mean of the C(max) for a 500mg dose administered to healthy male subjects in the fasted state compared to a lOOOmg dose of Zytiga® administered to healthy male subjects in the fasted state is selected from: 0.6 to 1.4, 0.7 to 1.3, 0.8 to 1.2 and 0.9 to 1.1.
  • the [D90] of the abiraterone acetate is greater than 300nm and less than one of: 7500nm, 7000nm, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm;
  • the [D4,3] of the abiraterone acetate is greater than 300nm and less than one of: 7000nm, 6000nm, 5000nm, 4000nm, 3000nm, 2500nm, 2400nm, 2200nm, 2000nm, 1900nm, 1700nm, 1500nm, 1300
  • a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma Cmax of 50-120 ng/ml.
  • a 500mg dose upon oral administration to a population of healthy male subjects in the fasted state, provides a median blood plasma tmax of 1 to 2.5 hrs.
  • a unit dosage form of a pharmaceutical composition comprising abiraterone acetate, wherein a 500mg dose, upon oral administration to a population of healthy male subjects in the fasted state, provides a mean blood plasma AUC (0- ⁇ ) of 240-650 h*ng/ml.
  • the unit dosage form contains 125mg of abiraterone acetate.
  • a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma Cmax is a value between 50 and 120 ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state; and a unit dosage form of a pharmaceutical composition comprising of abiraterone acetate, wherein the 90% confidence interval of the mean blood plasma AUC (0- ⁇ ) is a value between 240 and 650 h*ng/ml when a 500mg dose is administered to healthy male subjects in the fasted state.
  • the unit dosage forms described herein can contain an antioxidant (e.g., one or both of BHA and BHT).
  • an antioxidant e.g., one or both of BHA and BHT.
  • a method for treating castration resistant prostate cancer comprising administering to a patient in need thereof a therapeutically effective dose (e.g., 500mg) of the unit dosage form of abiraterone acetate described herein and a glucocorticoid.
  • a therapeutically effective dose e.g., 500mg
  • the glucocorticoid is selected from the group consisting of prednisone, prednisolone and methylprednisolone
  • the therapeutically effective dose is 500mg/day
  • the therapeutically effective dose is administered using dosage forms containing: lOOmg, 125mg, or 150mg of abiraterone acetate
  • the 500mg dose is administered using 1, 2, 3, 4, 5, or 6 unit dosage forms.
  • Described herein is a method for producing a composition comprising abiraterone acetate, the method comprising: dry milling a composition comprising abiraterone acetate, a millable grinding compound, a facilitating agent and one or both of an antioxidant and a sequestering agent in a mill, for a time period sufficient to produce a composition comprising milled abiraterone acetate, wherein the particle size of the abiraterone acetate is reduced by dry milling.
  • the [D90] of the abiraterone acetate in the milled composition is greater than 400nm and less than one of: 7500, 7000, 6000nm, 5000nm, 4500nm, 4000nm, 3000nm, 2000nm, 900nm, 800nm, and 700nm;
  • the [D50] of the abiraterone acetate in the milled composition is greater than lOOnm and is less than 3500nm, 3000nm, 2500nm, less than 1600nm, less than 1400nm, less than 1200nm, less than lOOOnm, less than 800nm, less than 500nm, less than 400nm, less than 300nm;
  • the dissolution rate of the abiraterone acetate in the milled composition is such that when a sample containing lOOmg of abiraterone acetate is tested in 900 ml of pH 4.5 phosphate buffer with
  • the particles of abiraterone acetate in the pharmaceutical compositions have a median particle size, determined on a particle volume basis ([Dso] or Dpo] or [D50]), equal or less than a size selected from the group consisting of: 5000nm, 4000nm, 3000 nm, 2500nm, 2400 nm, 2300nm, 2200nm, 2200nm, 2100nm, 2000nm, 1900nm, 1800nm, 1700nm, 1600nm, 1500nm, 1400nm, 1300nm, 1200nm, l lOOnm, lOOOnm, 900nm, 800nm, 700nm, 600nm, 500nm, 400 nm, 300nm and 200nm.
  • the [D50] is equal to or greater than 25nm or lOOnm or even 500nm. In various embodiments the [D50] is between: 5000nm and lOOnm, 3500nm and lOOnm, 2500nm and lOOnm, 1500nm and lOOnm, 1200nm and lOOnm, 1 lOOnm and lOOnm, lOOOnm and lOOnm, 800nm and lOOnm, 700nm and lOOnm, 600nm and lOOnm, 500nm and lOOnm.
  • the D[4,3] (volume mean diameter) in various embodiments is: less than 7000nm, less than 5000nm, less than 3500nm, less than 3000 nm, less than 2000 nm, less than 1000 or less than 300nm. In various cases, such as those described previously, the D[4,3] is greater than lOOnm or greater than 200nm.
  • the D[4,3] (volume mean diameter) is between: 7000nm and lOOOnm, 6000nm and 200nm, 5000nm and lOOOnm, 4000nm and lOOOnm, 3000nm and lOOOnm, 2000nm and lOOOnm, 1800nm and lOOOnm, 1600nm and lOOOnm, 1500nm and lOOOnm, 1500nm and 500nm, 4000nm and 2000nm, 4000nm and lOOnm, 25000nm and 500nm, 700nm and lOOnm, 600nm and lOOnm, 500nm and lOOnm lOOOnm and 200nm, 900nm and 200nm, 800nm and 200nm, 700nm and 200nm.
  • the [D90] ([D90] or D [9 o]) in various embodiments is: less than 8000nm, less than 7500nm, less than 7000nm, less than 6000nm, less than 4000 nm, less than 2000nm, less than lOOOnm, less than 500nm. In some cases, the D90 is between: 5500nm and 300nm, 5000nm and 500nm, 4500nm and 500nm, 4000nm and 200nm, 4500nm and 750nm, and 3500nm and 500nm. In various embodiments described herein the [D90] of the abiraterone acetate is less than 5000nm or less than 4000nm. In some embodiments the [D90] is: 6000nm-500nm, 5500nm-500nm, or 5000nm-500nm, and 4000-400nm.
  • the crystallinity profile of the abiraterone acetate is selected from the group consisting of: at least 20% of the abiraterone acetate is crystalline, at least 30% of the abiraterone acetate is crystalline, at least 40% of the abiraterone acetate is crystalline, at least 50% of the abiraterone acetate is crystalline, at least 60% of the abiraterone acetate is crystalline, at least 70% of the abiraterone acetate is crystalline, at least 75% of the abiraterone acetate is crystalline, at least 85% of the abiraterone acetate is crystalline, at least 90% of the abiraterone acetate is crystalline, at least 95% of the abiraterone acetate is crystalline and at least 98% of the abiraterone acetate is crystalline.
  • the crystallinity profile of the abiraterone acetate is selected from the group consisting
  • the amorphous content of the abiraterone acetate is selected from the group consisting of: less than 80% of the abiraterone acetate is amorphous, less than 70% of the abiraterone acetate is amorphous, less than 60% of the abiraterone acetate is amorphous, less than 50% of the abiraterone acetate is amorphous, less than 40% of the abiraterone acetate is amorphous, less than 30% of the abiraterone acetate is amorphous, less than 25% of the abiraterone acetate is amorphous, less than 15% of the abiraterone acetate is amorphous, less than 10% of the abiraterone acetate is amorphous, less than 5% of the abiraterone acetate is amorphous and less than 2% of the abiraterone acetate is amorphous.
  • the particles of abiraterone acetate are prepared by dry milling abiraterone acetate with a millable grinding compound and a facilitating agent in the presence of milling bodies. Additional components can be present during the milling and together the various components present during milling (with the exception of abiraterone acetate and the milling bodies) are referred to as a grinding matrix. In some cases, the milling produces particles of abiraterone acetate that are significantly reduced in size dispersed in grinding matrix. Because all of the components in the grinding matrix are pharmaceutically acceptable, pharmaceutical compositions can be prepared using the mixture of abiraterone acetate and grinding matrix produced by the milling.
  • the dry milling takes place in the presence of milling bodies; in other cases the particles are produced by milling in the absence of milling bodies, for example, by milling in jet mill or another type of mill, for example a mill that can reduce the particle size and/or increase the solublity of abiraterone acetate when the abiraterone acetate is milling in presence of millable grinding compound, which itself may or may not be reduced in particle size.
  • abiraterone acetate is milled with one or more millable grinding compounds selected from: lactose (e.g., lactose monohydrate or lactose anhydrous) and mannitol and one or more facilitating agents selected from sodium lauryl sulfate and povidone.
  • the milling in addition to reducing the particle size of the abiraterone acetate, reduces the particle size of one or more components of the grinding matrix.
  • the milling reduces the particles of one or more of the materials (e.g., lactose) used as the millable grinding compound.
  • abiraterone acetate is milled with lactose (e.g., lactose monohydrate) and sodium lauryl sulfate.
  • lactose e.g., lactose monohydrate
  • sodium lauryl sulfate e.g., sodium lauryl sulfate.
  • the abiraterone acetate can be present at 20-60% (w/w) the lactose at up to 80% (w/w) the mannitol at up to 80% (w/w) and the povidone and sodium lauryl sulfate each (or both) at 1-10% (w/w).
  • the abiraterone acetate is dry milled in the presence of one or more antioxidants and/or one or more sequestering agents (i.e., an agent that can sequester ions, e.g, metal ions) in addition to at least one millable grinding compound and at least one facilitating agent.
  • one or more of: butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) or mixtures thereof can be present during the dry milling.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • ascorbic acid fumaric acid, tartaric acid and citric acid (e.g, anhydrous citric acid) or mixtures thereof
  • both at least one antioxidant and at least one sequestering agent are present during milling.
  • the ascorbic acid, fumaric acid, tartaric acid and citric acid can be present at 8% or less on a w/w basis (e.g., 7%-0.1%, l%-0.1%, or 0.2% each or in combination) and the BHT and BHA can be present at 0.5% or less (e.g., 0.5% - 0.01%, 0.2% - 0.08%, 0.15%-0.05%, or 0.1% each or in combination).
  • One or more additional antioxidants and/or one or more additional sequestering agents can be added to the milled material after milling is completed.
  • the pharmaceutical composition can be a unit dosage form such as a capsule or tablet containing 50 - 500 mg of abiraterone acetate (e.g, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 1 15, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475 or 500 mg), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein.
  • abiraterone acetate e.g, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1 10, 1 15, 120, 125, 130, 135, 140, 145, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475 or 500 mg
  • Also described herein is a method for treating a patient comprising administering a daily dose of lOOOmg to 50mg of abiraterone acetate (e.g, 900, 850, 800, 750, 700, 650, 600, 550, 525, 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250, 225, 200, 150, 100, 90, 80, 70, 60, or 50 mg) in the form of a pharmaceutical composition described herein (e.g, by administering one or more units of a unit dosage form described herein comprising abiraterone acetate), wherein the abiraterone acetate has a size profile described herein and/or the dosage form has a dissolution profile described herein.
  • abiraterone acetate e.g, 900, 850, 800, 750, 700, 650, 600, 550, 525, 500, 475, 450, 425, 400,
  • the patient can also be treated with a glucocorticoid such as prednisone, prednisolone, or dexamethasone.
  • a glucocorticoid such as prednisone, prednisolone, or dexamethasone.
  • the patient can also be treated with methylprednisolone, for example at 5-15 mg/day (e.g., 5, 6, 7, 8, 9, 10 mg/day, for example two 4mg doses/day).
  • a patient e.g., a patient not suffering from hepatic impairment, is treated at 500mg/daily by administering four 125mg unit dosage forms of abiraterone acetate as described herein.
  • the AUC o- ⁇ for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 4-fold or less (3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
  • the AUC o- ⁇ (or AUC o-t) for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 8-fold or less (7-fold or less, 5-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
  • the Cmax for a single dose of a unit dosage form described herein (or an effective dose thereof, e.g., 4 x 125mg) when administered with a high-fat meal (57% fat, 825 calories) is 15-fold or less (13-fold or less or, 12-fold or less, 11-fold or less, 10-fold or less, 9-fold or less, 8-fold or less, 7-fold or less, 6-fold or less, 5-fold or less) higher than when administered in the fasted state.
  • the Cmax for a single dose of a unit dosage form described herein (or an approved dose thereof, e.g., 4 x 125mg) when administered with a low-fat meal (7% fat, 300 calories) is 6-fold or less (5-fold or less or 4-fold or less, 3-fold or less, 2-fold or less, 1.5-fold or less) higher than when administered in the fasted state.
  • the dissolution rate of a tablet containing lOOmg or 125 mg of abiraterone acetate when tested in 900 ml of pH 4.5 phosphate buffer with 0.1% -0.12% sodium lauryl sulfate (respectively) using USP Apparatus II at 75 rpm, is such that at least 90% or at least 95% of the abiraterone acetate dissolves in 20 min or less (e.g, 19 min or less, 18 min or less, 17 min or less, 16 min or less, 15 min or less, 14 min or less, 13 min or less, 11 min or less, 9 min or less). For example, 90% can dissolve in 9-19 minutes.
  • the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate.
  • at least 80% or at least 85% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 12 min or less, 11 min or less, 10 min or less, 9 min or less, 8 min or less, or 7 min or less). For example, 85% can dissolve in 7-14 minutes.
  • At least 80% or at least 85% of the abiraterone acetate in a 125mg unit dosage form dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 12 min or less, 11 min or less, 10 min or less, 9 min or less, 8 min or less, or 7 min or less) after storage at 4 weeks or more (e.g., 8 weeks or 12 weeks) at 25°C at 60% RH.
  • At least 95% of the abiraterone acetate dissolves in 15 min or less (e.g, 14 min or less, 13 min or less, 1 1 min or less, 9 min or less) after storage at 3 weeks or more (e.g., 6 weeks or 9 weeks) at 40°C at 75% RH.
  • 95% can dissolve in 8-14 min.
  • the dissolution rate given is for a fraction of a larger tablet (or multiple of a smaller tablet) providing 100-125mg of abiraterone acetate.
  • the coefficient of variation observed for a pharmaceutical composition described herein in one or more of Cmax, AUC(O-t), and AUC(O-co) will be less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, or less than 20% when administered to healthy patients in the fasted state.
  • a pharmaceutical composition described herein shows less variability in one or more of Cmax, AUC(O-t), and AUC(0- ⁇ ) relative to, e.g., a 250mg dosage form of Zytiga® (or a 1000 dose of a a 250mg dosage form of Zytiga®) in comparative pharmacokinetic testing.
  • the hardness of abiraterone tablets is between 100N and 190N (e.g., 110N to 180N).
  • the drug product intermediate can be prepared by dry milling the following materials: (A) abiraterone acetate at 5-60 weight percent, lactose (e.g., lactose monohydrate) at 30-95 weight percent, sodium lauryl sulfate at 0.1-15 weight percent; BHA at 0.001-1 weight percent, and BHT at 0.001-1 weight percent; (B) abiraterone acetate at 10-50 weight percent, lactose (e.g., lactose monohydrate) at 40-80 weight percent, sodium lauryl sulfate at 0.5-10 weight percent; BHA at 0.01-0.8 weight percent, and BHT at 0.01-0.8 weight percent; (C) abiraterone acetate at 20-40 weight percent, lactose (e.g., lactose monohydrate) at 50-70 weight percent, sodium lauryl sulfate at 2-8 weight percent; BHA at 0.05-0.5 weight percent, and BHT at 0.05-0.5 weight percent; (D
  • Drug product intermediate described above can be processed into tablets having the following materials: (A) abiraterone acetate at 5-50 weight percent, lactose (e.g., lactose monohydrate) at 5-80 weight percent, sodium lauryl sulfate at 0.1-10 weight percent, BHA at 0.001-1 weight percent, BHT at 0.001-1 weight percent, microcrystalline cellulose at 5-80 weight percent croscarmellose sodium at 0.5-20 weight percent, and sodium stearyl fumarate at 0.01-10 weight percent; (B) abiraterone acetate at 8-40 weight percent, lactose (e.g., lactose monohydrate) at 10- 60 weight percent, sodium lauryl sulfate at 0.5-8 weight percent, BHA at 0.01-0.05 weight percent, BHT at 0.01-0.5 weight percent, microcrystalline cellulose at 10-70 weight percent, croscarmellose sodium at 1-15 weight percent, and sodium stearyl fumarate at 0.05-5 weight percent; (C) abirater
  • the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: attritor mills (horizontal or vertical), nutating mills, tower mills, pearl mills, planetary mills, vibratory mills, eccentric vibratory mills, gravity-dependent- type ball mills, rod mills, roller mills and crusher mills.
  • the dry milling apparatus used to dry mill abiraterone acetate is a mill selected from the group consisting of: jet mills, spiral jet mills, micronisers or pulverizers.
  • the method is configured to produce the abiraterone acetate in a swing batch or continuous fashion.
  • the milling bodies within the milling apparatus are mechanically agitated by 1, 2 or 3 rotating shafts.
  • the milling bodies can be formed of a material selected from the group consisting of: ceramics, glasses, steels, polymers, ferromagnetics and metals and other suitable materials.
  • the milling bodies are steel balls having a diameter selected from the group consisting of: between 1 and 20 mm, between 2 and 1 mm and between 3 and 10 mm.
  • the milling bodies are zirconium oxide balls having a diameter selected from the group consisting of: between 1 and 20 mm, between 2 and 1 mm and between 3 and 10 mm.
  • the milling time period is a range selected from the group consisting of: between 10 minutes and 6 hours, between 10 minutes and 2 hours, between 10 minutes and 90 minutes, between 10 minutes and 1 hour, between 10 minutes and 45 minutes, between 10 minutes and 30 minutes, between 5 minutes and 30 minutes, between 5 minutes and 20 minutes, between 2 minutes and 10 minutes, between 2 minutes and 5 minutes, between 1 minutes and 2 minutes.
  • the grinding matrix is a single material or is a mixture of two or more materials in any proportion.
  • the single material or a mixture of two or more materials is selected from the group consisting of: mannitol, sorbitol, isomalt, xylitol, maltitol, lactitol, erythritol, arabitol, ribitol, glucose, fructose, mannose, galactose, anhydrous lactose, lactose monohydrate, sucrose, maltose, trehalose, and maltodextrins.
  • the single material or mixture of two or more materials is selected from the group consisting of: dextrin, inulin, dextrates, polydextrose, starch, wheat flour, corn flour, rice flour, rice starch, tapioca flour, tapioca starch, potato flour, potato starch, other flours and starches, milk powder, skim milk powders, other milk solids and derivatives, soy flour, soy meal or other soy products, cellulose, microcrystalline cellulose, microcrystalline cellulose based co-blended materials, pregelatinized (or partially gelatinized) starch, hypromellose, carboxymethyl cellulose, hydroxypropyl cellulose, citric acid, tartaric acid, malic acid, maleic acid, fumaric acid, ascorbic acid, succinic acid, sodium citrate, sodium tartrate, sodium malate, sodium ascorbate, potassium citrate, potassium tartrate, potassium malate, sodium acetate, potassium ascorbate, sodium carbonate, potassium carbonate, magnesium carbonate,
  • the concentration of the single (or first) component of the grinding matrix is selected from the group consisting of: 5 - 99 % w/w, 10 - 95 % w/w, 15 - 85 % w/w, of 20 - 80% w/w, 25 - 75 % w/w, 30 - 60% w/w, 40 -50% w/w. In some embodiments, the
  • concentration of the second or subsequent component of the grinding matrix is selected from the group consisting of: 5 - 50 % w/w, 5 - 40 % w/w, 5 - 30 % w/w, of 5 - 20% w/w, 10 - 40 % w/w, 10 -30% w/w, 10 -20% w/w, 20 - 40% w/w, or 20 - 30% w/w or if the second or subsequent material is a surfactant or water soluble polymer the concentration is selected from 0.1 - 10 % w/w, 0.1 -5 % w/w, 0.1 -2.5 % w/w, of 0.1 - 2% w/w, 0.1 - 1 %, 0.5 -5% w/w, 0.5 -3% w/w, 0.5 -2% w/w, 0.5 - 1.5%, 0.5 -1 % w/w, of 0.75 - 1.25 % w/w, 0.75
  • abiraterone acetate is milled in the presence of:
  • Lactose monohydrate or lactose monohydrate combined with at least one material selected from the group consisting of: xylitol; lactose anhydrous; microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n- lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl s
  • tristyrylphosphate ester tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines .
  • Lactose anhydrous or lactose anhydrous combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; microcrystalline cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n- lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl
  • tristyrylphosphate ester tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalky lamines .
  • tristyrylphosphate ester tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines .
  • Sucrose or sucrose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol; microcrystalline cellulose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
  • hydrophobic collodial silica sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl na
  • Glucose or glucose combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol; microcrystalline cellulose; sucrose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
  • hydrophobic collodial silica sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl na
  • Sodium chloride or sodium chloride combined with at least one material selected from the group consisting of: lactose monohydrate; lactose anhydrous; mannitol; microcrystalline cellulose; sucrose; glucose; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl
  • lactose monohydrate lactose anhydrous
  • mannitol microcrystalline cellulose
  • sucrose glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium
  • microcrystalline cellulose sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG 6000, sodium
  • Microcrystallme cellulose or microcrystallme cellulose combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; lactose anhydrous; mannitol; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether;
  • polyoxyl 10 stearyl ether sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and Polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium
  • Kaolin combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystallme cellulose; sucrose; glucose; sodium chloride; talc; kaolin; calcium carbonate; malic acid;
  • tartaric acid trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; Polyoxyl 100 stearyl ether; Polyoxyl 10 stearyl ether; sodium n-lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate;
  • Hydrophobic collodial silica sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulfate and PEG 6000, sodium lauryl sulfate and PEG 8000, sodium lauryl sulfate and PEG 10000, sodium lauryl sulfate and polyoxyl 100 stearyl ether, sodium lauryl sulfate and poloxamer 407, sodium lauryl sulfate and poloxamer 338, sodium lauryl sulfate and poloxamer 188; poloxamer 407, poloxamer 338, poloxamer 188, alkyl na
  • (k) Talc combined with at least one material selected from the group consisting of: lactose monohydrate; xylitol; lactose anhydrous; mannitol; microcrystallme cellulose; sucrose; glucose; sodium chloride; kaolin; calcium carbonate; malic acid; tartaric acid; trisodium citrate dihydrate; D,L-malic acid; sodium pentane sulfate; sodium octadecyl sulfate; polyoxyl 100 stearyl ether; polyoxyl 10 stearyl ether; sodium n- lauroyl sacrosine; lecithin; docusate sodium; polyoxyl-40-stearate; hydrophobic collodial silica; sodium lauryl sulfate or other alkyl sulfate surfactants with a chain length between C5 to CI 8; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40 stearate
  • tristyrylphosphate ester tristyrylphenol ethoxylate sulfate; bis(2-hydroxyethyl) tallowalkylamines .
  • the abiraterone acetate is dry milled with one or more additional materials is selected from the group consisting of: a material considered to be 'Generally Regarded as Safe' (GRAS) for pharmaceutical products.
  • GRAS Safe'
  • the dry milling of abiraterone acetate takes place in the presence of a facilitating agent or combination of facilitating agents.
  • the facilitating agent is selected from the group consisting of: a glidant, a surfactant, a polymer, and/or a lubricant.
  • the facilitating agent is selected from the group consisting of: colloidal silicon dioxide, sodium stearate and talc.
  • the facilitating agent is selected from the group consisting of: benzethonium chloride, docusate sodium, polyethylene alkyl ethers, sodium lauryl sulfate, tricaprylin, alpha tocopherol, glyceryl monooleate, myristyl alcohol, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene stearates, polyoxyethylene castor oil derivatives, polyoxyl 15 hydroxystearate, polyoxylglycerides, polysorbates, propylene glycol dilaurate, sorbitan esters, sucrose palmitate, vitamin E polyethylene glycol succinate, polyethylene glycols (PEG), poloxamers, poloxamines, sarcosine based surfactants, polysorbates, aliphatic alcohols, alkyl and aryl sulfates, alkyl and aryl polyether sulfonates and other sulfate surfactants, trimethyl ammonium
  • the facilitating agent is selected from the group consisting of sodium stearyl sulfate, sodium stearyl fumarate, magnesium stearate, talc, myristic acid, sodium cetyl sulfate, sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate, glycerol distearate glyceryl palmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate, benzalkonium chloride, cetyl trimethylammonium bromide, cetyl trimethylammonium chloride, cetrimide, cetylpyridinium chloride,
  • the facilitating agent is selected from the list of: polyvinylpyrrolidones (PVP), polyvinylalcohol, acrylic acid based polymers and copolymers of acrylic acid.
  • PVP polyvinylpyrrolidones
  • acrylic acid based polymers and copolymers of acrylic acid.
  • the facilitating agent has a concentration during dry milling selected from the group consisting of: 0.1 -10 % w/w, 0.1 -5 % w/w, 0.1 -2.5 % w/w, of 0.1 - 2% w/w, 0.1 -1 %, 0.5 -5% w/w, 0.5 -3% w/w, 0.5 -2% w/w, 0.5 - 1.5%, 0.5 -1 % w/w, of 0.75 - 1.25 % w/w, 0.75 -l% and l% w/w.
  • a facilitating agent is used or combination of facilitating agents is used during dry milling.
  • the facilitating agent is added during dry milling.
  • the facilitating agent is added to the dry milling at a time selected from the group consisting of: with 1-5 % of the total milling time remaining, with 1-10 % of the total milling time remaining, with 1-20 % of the total milling time remaining, with 1-30 % of the total milling time remaining, with 2-5% of the total milling time remaining, with 2-10% of the total milling time remaining, with 5-20% of the total milling time remaining and with 5-20% of the total milling time remaining.
  • facilitating agents include, but are not limited to providing better dispersibility, control of agglomeration, the release or retention of the active particles from the delivery matrix.
  • facilitating agents include, but are not limited to: sodium lauryl sulfate, cross-linked PVP (crospovidone), cross linked sodium carboxymethylcellulose
  • croscarmellose sodium sodium starch glycolate, povidone (PVP), povidone K12, povidone 17, povidone K25, povidone 29/32 and povidone 30, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, sodium stearyl lactylate, zinc stearate, sodium stearate or lithium stearate, other solid state fatty acids such as oleic acid, lauric acid, palmitic acid, erucic acid, behenic acid, or derivatives (such as esters and salts), amino acids such as leucine, isoleucine, lysine, valine, methionine, phenylalanine, aspartame or acesulfame K.
  • PVP povidone
  • K12 povidone 17
  • povidone K25 povidone K25
  • povidone 29/32 and povidone 30 stearic acid
  • magnesium stearate calcium stearate
  • the disclosure includes a method of treating a human in need of such treatment comprising the step of administering to the human an effective amount of a pharmaceutical composition as described herein for treatment of castration resistant prostate cancer.
  • the treatment can include administering 500mg of abiraterone acetate daily (e.g., in 1 or 2 or 4 equal doses (e.g., one unit dose containing 500mg, two unit doses containing 250mg of abiraterone acetate each, or four unit doses containing 125mg of abiraterone acetate each) .
  • the patient can also be treated with a glucocorticoid, e.g, prednisone, dexamethasone or prednisolone (e.g., at 5 mg, twice daily).
  • a glucocorticoid e.g, prednisone, dexamethasone or prednisolone
  • the patient can be treated with methylprednisolone (e.g. at 4 mg twice daily).
  • the patient can also be treated with other chemotherapeutic agents or other agents for the treatment of cancer (e.g., prostate cancer).
  • the disclosure also includes a method for treating breast cancer (e.g., metastatic breast cancer) and ovarian cancer (e.g., epithelial ovarian cancer) using a composition described herein.
  • breast cancer e.g., metastatic breast cancer
  • ovarian cancer e.g., epithelial ovarian cancer
  • the disclosure comprises the use of a pharmaceutical composition as described herein in the manufacture of a medicament for the treatment of a human in need of such treatment.
  • the disclosure comprises a method for manufacturing a pharmaceutical composition as described herein comprising the step of combining a composition comprising abiraterone acetate prepared by a method described herein or a composition as described herein, together with one of a diluent, lubricant, excipient, disintegrant, wetting agent, to produce a pharmaceutically acceptable dosage form.
  • the disclosure described herein may include one or more ranges of values (e.g. size, concentration etc.).
  • a range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range that lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
  • “Therapeutically effective amount” as used herein with respect to methods of treatment and in particular drug dosage shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount,” administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a “therapeutically effective amount” by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
  • dry mill or variations, such as “dry milling,” should be understood to refer to milling in at least the substantial absence of liquids. If liquids are present, they are present in such amounts that the contents of the mill retain the characteristics of a dry powder.
  • millable means that the grinding matrix is capable of being reduced in size under the dry milling conditions of the method of the disclosure.
  • the milled grinding matrix is of a comparable particle size to the abiraterone acetate.
  • the particle size of the matrix is substantially reduced but not as small as the abiraterone acetate.
  • Figure 1 is a graph of the results of particle size analysis of unmilled abiraterone acetate and abiraterone acetate in formula 1 and formula 2 of Example 1.
  • Figure 2 is a graph of the results of dissolution rate measurements for abiraterone acetate tablets as described in Example 3.
  • Figures 3 A and 3B are graphs depicting the results of stability studies described in Example 6.
  • median particle size is defined as the median particle diameter as determined on an equivalent spherical particle volume basis. Where the term median is used, it is understood to describe the particle size that divides the population in half such that 50 % of the population on a volume basis is greater than or less than this size.
  • the median particle size is written as: [D50] or Dpo] or [D50], D50, D(0.50) or D[0.5] or similar. As used herein [D50] or D[50] or [D50], D50, D(0.50) or D[0.5] or similar shall be taken to mean median particle size.
  • Dx of the particle size distribution refers to the xth percentile of the distribution on a volume basis; thus, D90 refers to the 90 th percentile, D95 refers to the 95 th percentile, and so forth. Taking D90 as an example this can often be written as, [D90] or Dpo] or [D90], D(0.90) or D[0.9] or similar. With respect to the median particle size and Dx an upper case D or lowercase d are interchangeable and have the same meaning. Another commonly used way of describing a particle size distribution measured by laser diffraction, or an equivalent method known in the art, is to describe what % of a distribution is under or over a nominated size.
  • the term "percentage less than” also written as "% ⁇ ” is defined as the percentage, by volume, of a particle size distribution under a nominated size -for example the % ⁇ 1000 nm.
  • the term “percentage greater than” also written as "%>” is defined as the percentage, by volume, of a particle size distribution over a nominated size -for example the % > 1000 nm.
  • the term D(3,2) is referred to as the area- weighted mean size or the Sauter diameter; the term D(4,3) is referred to as the volume-weighted mean size. Detailed descriptions of how these values are calculated are known in the art and can be found in, for example, ISO 9276-2:2014(E).
  • the particle size can be easily measured.
  • the active material has poor water solubility and the matrix it is milled in has good water solubility the powder can simply be dispersed in an aqueous solvent. In this scenario the matrix dissolves leaving the active material dispersed in the solvent. This suspension can then be measured by techniques such as PCS or laser diffraction.
  • Suitable methods to measure an accurate particle size where the active material has substantive aqueous solubility or the matrix has low solubility in a water based dispersant are outlined below.
  • image analysis could be used to obtain information about the particle size distribution of the active material.
  • Suitable image measurement techniques might include transmission electron microscopy (TEM), scanning electron microscopy (SEM), optical microscopy and confocal microscopy.
  • TEM transmission electron microscopy
  • SEM scanning electron microscopy
  • optical microscopy optical microscopy
  • confocal microscopy In addition to these standard techniques some additional technique would be required to be used in parallel to differentiate the active material and matrix particles.
  • possible techniques could be elemental analysis, Raman spectroscopy, FTIR spectroscopy or fluorescence spectroscopy.
  • the process results in the abiraterone acetate having an improved dissolution profile.
  • An improved dissolution profile has significant advantages including, in some cases, the improvement of bioavailability of the abiraterone acetate in vivo.
  • Standard methods for determining the dissolution profile of a material in vitro are available in the art.
  • a suitable method to determine an improved dissolution profile in vitro may include determining the concentration of the sample material in a solution over a period of time and comparing the results from the sample material to a control sample. An observation that peak solution concentration for the sample material was achieved in less time than the control sample would indicate that the sample material has an improved dissolution profile.
  • the test sample can be the unit dosage form containing abiraterone acetate with grinding matrix and/or other additives that has been subject to the processes of the disclosure described here, as well as excipients to manufacture the final dosage form.
  • a control sample can be as a physical of the components in the measurement sample with the same relative proportions of active, matrix and/or additive as the measurement sample.
  • the control sample can also be the commercially available dosage form, Zytiga® tablets, cut to represent an equivalent quantity of abirateratone acetate as the test sample. Standard methods for determining the improved dissolution profile of a material in vivo are available in the art.
  • Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
  • Suitable methods may include X-ray diffraction, differential scanning calorimetry, and Raman or IR spectroscopy.
  • an appropriate grinding matrix affords particular advantageous applications of the method of the present disclosure.
  • a highly advantageous aspect of the present disclosure is that certain grinding matrixes appropriate for use in the method of the disclosure are also appropriate for use in a medicament.
  • the present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and the grinding matrix or in some cases the abiraterone acetate and a portion of the grinding matrix, medicaments so produced, and methods of treatment using the medicament.
  • the medicament may include only the milled abiraterone acetate together with the milled grinding matrix or, more preferably, the milled abiraterone acetate and milled grinding matrix may be combined with one or more pharmaceutically acceptable carriers, as well as any desired excipients or other like agents commonly used in the preparation of medicaments.
  • At least one component of the grinding matrix is harder than the abiraterone acetate, and is thus capable of reducing the particle size of the abiraterone acetate under the dry milling conditions of the disclosure.
  • the millable grinding matrix affords the advantage of the present disclosure through a second route, with the smaller particles of grinding matrix produced under the dry milling conditions enabling greater interaction with the abiraterone acetate.
  • the quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of physical degradation of the grinding matrix is sufficient to inhibit re-agglomeration of the particles of the active material
  • the quantity of the grinding matrix relative to the quantity of abiraterone acetate, and the extent of size reduction of the grinding matrix is sufficient to inhibit re-agglomeration of the particles of the active material.
  • the grinding matrix can include one or more anti-oxidants and/or one or more sequestering agents
  • the grinding matrix has a low tendency to agglomerate during dry milling. While it is difficult to objectively quantify the tendency to agglomerate during milling, it is possible to obtain a subjective measure by observing the level of "caking" of the grinding matrix in the milling chamber of the mill as dry milling progresses.
  • the grinding matrix may be an inorganic or organic substance.
  • the milling bodies are preferably chemically inert and rigid.
  • chemically-inert means that the milling bodies do not react chemically with the abiraterone acetate or the grinding matrix.
  • the milling bodies are essentially resistant to fracture and erosion in the milling process.
  • the milling bodies are desirably provided in the form of bodies which may have any of a variety of smooth, regular shapes, flat or curved surfaces, and lacking sharp or raised edges.
  • suitable milling bodies can be in the form of bodies having ellipsoidal, ovoid, spherical or right cylindrical shapes.
  • the milling bodies are provided in the form of one or more of beads, balls, spheres, rods, right cylinders, drums or radius-end right cylinders (i.e., right cylinders having hemispherical bases with the same radius as the cylinder).
  • the milling bodies desirably have an effective mean diameter between about 0.1 and 30 mm, more preferably between about 1 and about 15 mm, still more preferably between about 3 and 10 mm.
  • the milling bodies may comprise various substances such as ceramic, glass, metal or polymeric compositions, in a particulate form.
  • Suitable metal milling bodies are typically spherical and generally have good hardness (i.e. RHC 60-70), roundness, high wear resistance, and narrow size distribution and can include, for example, balls fabricated from type 52100 chrome steel, type 304, 316 or 440C stainless steel or type 1065 high carbon steel.
  • Ceramics for example, can be selected from a wide array of ceramics desirably having sufficient hardness and resistance to fracture to enable them to avoid being chipped or crushed during milling and also having sufficiently high density. Suitable densities for milling bodies can range from about 1 to 15 g/cm 3 , preferably from about 1 to 8 g/cm 3 . Ceramics can be selected from steatite, aluminum oxide, zirconium oxide, zirconia-silica, yttria-stabilized zirconium oxide, magnesia-stabilized zirconium oxide, silicon nitride, silicon carbide, cobalt-stabilized tungsten carbide, and the like, as well as mixtures thereof.
  • Glass milling bodies are spherical (e.g. beads), have a narrow size distribution, are durable, and include, for example, lead-free soda lime glass and borosilicate glass.
  • Polymeric milling bodies are preferably substantially spherical and can be selected from a wide array of polymeric resins having sufficient hardness and friability to enable them to avoid being chipped or crushed during milling, abrasion-resistance to minimize attrition resulting in contamination of the product, and freedom from impurities such as metals, solvents, and residual monomers.
  • Milling bodies can be formed from polymeric resins.
  • Polymeric resins for example, can be selected from crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene, styrene copolymers, polyacrylates such as polymethylmethacrylate, polycarbonates, polyacetals, vinyl chloride polymers and copolymers, polyurethanes, polyamides, high density polyethylenes, polypropylenes, and the like.
  • polymeric milling bodies to grind materials down to a very small particle size is disclosed, for example, in U.S. patents 5,478,705 and 5,500,331.
  • Polymeric resins typically can have densities ranging from about 0.8 to 3.0 g/cm 3 . Higher density polymeric resins are generally preferred.
  • the milling bodies can be composite bodies comprising dense core bodies having a polymeric resin adhered thereon.
  • Core particles can be selected from substances known to be useful as milling bodies, for example, glass, alumina, zirconia silica, zirconium oxide, stainless steel, and the like. Core substances have densities greater than about 2.5 g/cm 3 .
  • the milling bodies are formed from a ferromagnetic substance, thereby facilitating removal of contaminants arising from wear of the milling bodies by the use of magnetic separation techniques.
  • metals have the highest specific gravities, which increase grinding efficiency due to increased impact energy.
  • Metal costs range from low to high, but metal contamination of final product can be an issue.
  • Glasses are advantageous from the standpoint of low cost and the availability of small bead sizes as low as 0.004 mm.
  • specific gravity of glasses is lower than other bodies and significantly more milling time is required.
  • ceramics are advantageous from the standpoint of low wear and contamination, ease of cleaning, and high hardness. Dry Milling
  • the abiraterone acetate and grinding matrix in the form of crystals, powders, or the like, are combined in suitable proportions with or without a plurality of milling bodies in a milling chamber that is mechanically agitated for a
  • a milling apparatus is used to impart motion to contents of the mill including any milling bodies by the external application of agitation, a stream of dry gas or other force, whereby various translational, rotational or inversion motions or combinations thereof are applied to the milling chamber and its contents, or by the internal application of agitation through a rotating shaft terminating in a blade, propeller, impeller or paddle or by a combination of both actions.
  • motion imparted to the milling bodies or gas flowing through the milling system can result in application of shearing forces as well as multiple impacts or collisions having significant intensity between the mill components, any milling bodies utilized and the particles of abiraterone acetate and the grinding matrix.
  • the nature and intensity of the forces applied to the abiraterone acetate and the grinding matrix is influenced by a wide variety of processing parameters including: the type of milling apparatus; the intensity of the forces generated, the kinematic aspects of the process; the size, density, shape, and composition of any milling bodies used; the weight ratio of the abiraterone acetate and grinding matrix mixture to any milling bodies used; the duration of milling; the physical properties of both the abiraterone acetate and the grinding matrix; the atmosphere present during milling; and other factors.
  • the mill is capable of repeatedly or continuously applying mechanical compressive forces and shear stress to the abiraterone acetate and the grinding matrix.
  • dry milling being carried out by way of a ball mill.
  • this type of mill are attritor mills, nutating mills, tower mills, planetary mills, vibratory mills, gravity-dependent-type ball mills, jet mills, rod mills, roller mills or crusher mills, jet mills and pulverizing mills. It will be appreciated that dry milling in accordance with the method of the disclosure may also be achieved by any suitable milling method or means.
  • the particle size of the abiraterone acetate prior to dry milling according to the methods described herein is less than about 1000 ⁇ , as determined by sieve analysis. If the particle size of the abiraterone acetate is greater than about 1000 ⁇ , then it is preferred that the particles of the abiraterone acetate substrate be reduced in size to less than 1000 ⁇ using another particle size reduction method prior to dry milling according to the methods described herein.
  • Agglomerates comprising particles of abiraterone acetate having a particle size within the ranges specified herein, should be understood to fall within the scope of the present disclosure, regardless of whether the agglomerates exceed the ranges specified above.
  • the abiraterone acetate and the grinding matrix are dry milled for the shortest time necessary to minimize any possible contamination from the mill process and/or any milling bodies utilized. This time varies greatly, depending on the abiraterone acetate and the grinding matrix, and may range from as short as 1 minute to several hours.
  • Suitable rates of agitation and total milling times are adjusted for the type and size of milling apparatus, the type and size of any milling media utilized, the weight ratio of the abiraterone acetate and grinding matrix mixture to the plurality of milling bodies that may be utilized, the chemical and physical properties of the abiraterone acetate and grinding matrix, and other parameters that may be optimized empirically.
  • the grinding matrix (the materials milled together with abiraterone acetate) is not separated from the abiraterone acetate but is maintained with the abiraterone acetate in the final product. In some embodiments the grinding matrix is considered to be Generally Regarded as Safe (GRAS) for pharmaceutical products.
  • GRAS Generally Regarded as Safe
  • the grinding matrix is separated from the abiraterone acetate.
  • the unmilled grinding matrix is separated from the abiraterone acetate.
  • at least a portion of the milled grinding matrix is separated from the abiraterone acetate.
  • any portion of the grinding matrix may be removed, including but not limited to 10%, 25%, 50%, 75%, or substantially all of the grinding matrix.
  • a significant portion of the milled grinding matrix may comprise particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate.
  • the portion of the milled grinding matrix to be separated from the particles comprising the abiraterone acetate comprises particles of a size similar to and/or smaller than the particles comprising the abiraterone acetate
  • separation techniques based on size distribution are inapplicable.
  • the method of the present disclosure may involve separation of at least a portion of the milled grinding matrix from the abiraterone acetate by techniques including, but not limited to, electrostatic separation, magnetic separation, centrifugation (density separation), hydrodynamic separation, and froth flotation.
  • the step of removing at least a portion of the milled grinding matrix from the abiraterone acetate may be performed through means such as selective dissolution, washing, or sublimation.
  • grinding matrix that has two or more components where at least one component is water soluble and at least one component has low solubility in water can be used.
  • washing can be used to remove the matrix component soluble in water leaving the abiraterone acetate dispersed in the remaining matrix components.
  • the matrix with low solubility is a functional excipient.
  • the grinding matrix is appropriate for use in the method of the disclosure are also pharmaceutically acceptable and thus appropriate for use in a medicament.
  • the method of the present disclosure does not involve complete separation of the grinding matrix from the abiraterone acetate, the present disclosure encompasses methods for the production of a medicament incorporating both the abiraterone acetate and at least a portion of the milled grinding matrix, medicaments so produced and methods of treatment of an animal, including man, using a therapeutically effective amount of said abiraterone acetate by way of said medicaments.
  • compositions including such materials including compositions comprising such materials together with the grinding matrix with or without milling aids, facilitating agents, with at least a portion of the grinding matrix or separated from the grinding matrix.
  • the medicaments of the present disclosure may include the pharmaceutically acceptable material, optionally together with the grinding matrix or at least a portion of the grinding matrix, with or without milling aids, facilitating agents, combined with one or more pharmaceutically acceptable carriers, as well as other agents commonly used in the preparation of
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier is suitable for parenteral administration, intravenous, intraperitoneal, intramuscular, sublingual, pulmonary, transdermal or oral administration.
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for the manufacture of medicaments is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutically acceptable material, use thereof in the manufacture of a pharmaceutical composition according to the disclosure is contemplated.
  • compositions may include one or more of the following examples:
  • surfactants and polymers including, but not limited to polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate, polyvinylalcohol, crospovidone, polyvinylpyrrolidone- polyvinylacrylate copolymer, cellulose derivatives,
  • hydroxypropylmethyl cellulose hydroxypropyl cellulose, carboxymethylethyl cellulose, hydroxypropyllmethyl cellulose phthalate, polyacrylates and
  • polymethacrylates polymethacrylates, urea, sugars, polyols, and their polymers, emulsifiers, sugar gum, starch, organic acids and their salts, vinyl pyrrolidone and vinyl acetate
  • binding agents such as various celluloses and cross-linked polyvinylpyrrolidone
  • microcrystalline cellulose and or
  • sweeteners such as any natural or artificial sweetener including sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame ; and or
  • preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic chemicals such as phenol, or quarternary compounds such as benzalkonium chloride; and or
  • Diluents such as pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing; and or
  • wetting agents such as corn starch, potato starch, maize starch, and modified starches, and mixtures thereof; and or
  • disintegrants such as croscarmellose sodium, crospovidone, sodium starch glycolate, and or
  • effervescent agents such as effervescent couples such as an organic acid (e.g., citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts), or a carbonate (e.g. sodium carbonate, potassium carbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate) or bicarbonate (e.g. sodium bicarbonate or potassium bicarbonate); and or
  • organic acid e.g., citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts
  • a carbonate e.g. sodium carbonate, potassium carbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate
  • bicarbonate e.g. sodium bicarbonate or potassium bicarbonate
  • abiraterone acetate disclosure may be varied in accordance with the nature of the abiraterone acetate, as well as the potential increased efficacy due to the advantages of providing and administering the abiraterone acetate (e.g., increased solubility, more rapid dissolution, increased surface area of the abiraterone acetate, etc.).
  • therapeutically effective amount will refer to an amount of abiraterone acetate required to effect a therapeutic response in an animal.
  • Amounts effective for such a use will depend on: the desired therapeutic effect; the route of administration; the potency of the abiraterone acetate; the desired duration of treatment; the stage and severity of the disease being treated; the weight and general state of health of the patient; and the judgment of the prescribing physician.
  • the abiraterone acetate compositions of the disclosure are rapidly absorbed.
  • the abiraterone acetate compositions of the disclosure have a Tmax , when administered to an adult male in the fasted state, of less than about 2.5 hours (about 3 hours to about 2 hours), less than about 2.0 hours, less than about 1.75 hours, less than about 1.5 hours, less than about 1.25 hours, and more than about 1.0 hour, for example between 1.5 and 2.0 hrs
  • the abiraterone acetate compositions of the disclosure exhibit increased bioavailability (AUC) and require smaller doses as compared to prior conventional compositions administered at the same dose (e.g., Zytiga®).
  • AUC bioavailability
  • Zytiga® a dose administered at the same dose
  • an AUC and/or a Cmax similar to Zytiga® can be achieved at lower dose than for Zytiga®.
  • the pharmaceutical compositions described herein administered at a lower dose than Zytiga provide comparable systemic exposure.
  • a 500mg dose can be bioequivalent to a 1 ,000mg dose of Zytiga®.
  • Any drug composition can have adverse side effects.
  • lower doses of drugs which can achieve the same or better therapeutic effect as those observed with larger doses of conventional compositions are desired.
  • Such lower doses can be realized with the compositions of the disclosure because the greater bioavailability observed with the compositions as compared to conventional drug formulations means that smaller doses of drug are required
  • the Pharmacokinetic Profiles of the Compositions of the Disclosure May be less Affected by the Fed or Fasted State of the Subject Ingesting the Compositions
  • the disclosure encompasses abiraterone acetate compositions wherein the pharmacokinetic profile of the composition is less affected by the fed or fasted state of a subject ingesting the composition compared to Zytiga®. This means that there is a less difference in the quantity of composition or the rate of composition absorption when the compositions are administered in the fed versus the fasted state. Thus, in some cases the compositions of the disclosure reduce the effect of food on the pharmacokinetics of the composition compared to Zytiga®.
  • the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUC0 may be less for an abiraterone acetate dosage form described herein than for Zytiga®.
  • the geometric mean coefficient of variation in one or more of Cmax, AUCO-t and AUC0- oo can be 10%-50% less (at least 10% less, 10%-30% less, or 10%-20% less) than for Zytiga®. (Calculated as CV (Zytiga®)-CV (present dosage form)/CV (Zytiga®) x 100%).
  • Any standard pharmacokinetic protocol can be used to determine blood plasma concentration profile in humans following administration of a composition, and thereby establish whether that composition meets the pharmacokinetic criteria set out herein.
  • a randomized single-dose crossover study can be performed using a group of healthy adult human subjects. The number of subjects should be sufficient to provide adequate control of variation in a statistical analysis, and is typically about 10 or greater, although for certain purposes a smaller group can suffice.
  • Each subject receives by oral administration at time zero a single dose (e.g., 100 mg) of a test formulation of composition, normally at around 8 am following an overnight fast. The subjects continue to fast and remain in an upright position for about 4 hours after administration of the composition.
  • Blood samples are collected from each subject prior to administration (e.g., 15 minutes) and at several intervals after administration. For the present purpose it is to take several samples within the first hour, and to sample less frequently thereafter. Illustratively, blood samples could be collected at 15, 30, 45, 60, and 90 minutes after administration, then every hour from 2 to 10 hours after administration. Additional blood samples may also be taken later, for example at 12, 24, 36 and 48 hours after administration. If the same subjects are to be used for study of a second test formulation, a period of at least 7 days should elapse before administration of the second formulation. Plasma is separated from the blood samples by centrifugation and the separated plasma is analyzed for composition by a validated high performance liquid chromatography (HPLC) or liquid chromatography mass spectrometry (LCMS) procedure. Plasma concentrations of composition referenced herein are intended to mean total concentrations including both free and bound composition.
  • HPLC high performance liquid chromatography
  • LCMS liquid chromatography mass spectrometry
  • Medicaments of the disclosure can be administered to animals, including man, in any pharmaceutically acceptable manner, such as orally, rectally, pulmonary, intravaginally, locally (powders, ointments or drops), transdermal, parenteral administration, intravenous,
  • intraperitoneal, intramuscular, sublingual or as a buccal or nasal spray is included.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, pellets, and granules. Further, incorporating any of the normally employed excipients, such as those previously listed, and generally 5-95% of the biologically active agent, and more preferably at a concentration of 10%-75% will form a pharmaceutically acceptable non-toxic oral composition.
  • the particles comprising the abiraterone acetate may require further stabilization once the solid carrier has been substantially removed to ensure the elimination, or at least minimization of particle agglomeration.
  • Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the percentages shown in Table 1 to prepare a drug product intermediate for use in the preparation of tablets. Both lots of material were milled in a Union Process IS attritor mill with a 0.5 gallon jacket-cooled tank. 200g batches were milled with milling bodies for 40 minutes.
  • Example 2 Particle size analysis of milled and unmilled Abiraterone Acetate
  • the particle size distribution of the abiraterone acetate in the two drug product intermediate lots described in Example 1 were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Additionally, an unmilled blend of abiraterone acetate, lactose monohydrate and sodium lauryl sulfate was measured. All three samples were measured using the method as follows: the dispersant used was an aqueous solution of 0.1% povidone K30. Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube.
  • the tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off.
  • the particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15% was reached and remained constant.
  • the stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported. Table 2 and Figure 1 show the particle size distributions; the data shows over a 10-fold reduction in particle size.
  • the milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling.
  • the granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce lOOmg abiraterone acetate tablets having the composition shown in Table 3.
  • the dissolution rates of the tablets prepared as described above were measured using the method listed on the FDA website for abiraterone acetate tablets, 250mg; USP Apparatus II, 50 rpm in 900mL of pH 4.5 buffer with 0.25% sodium lauryl sulfate. Samples were analyzed by UV at 270nm. Additionally, for comparison purposes, Zytiga® tablets were tested with the same dissolution conditions. The results of this analysis are shown in Table 4 and Figure 2. Full dissolution (>85% dissolved) was achieve in 10-20 minutes for the two tablet formulations contained milled abiraterone acetate, compared to Zytiga® which had full dissolution (>85% dissolved) in 60 minutes.
  • Abiraterone acetate was dry milled in the presence of lactose monohydrate and sodium lauryl sulfate in the amounts shown in Table 5 to prepare a drug product intermediate for use in the preparation of tablets for use in Phase I testing.
  • the material was milled in a Union Process 1 S attritor mill with a 1.5 gallon jacket-cooled tank. The material was milled with milling bodies for 40 minutes.
  • the particle size distribution of the abiraterone acetate in the milled drug product intermediate was measured with a Micromeritics Saturn DigiSizer II 5205 particle size analyzer configured with an AquaPrep II sample cell.
  • the instrument sample reservoir was filled with dispersant solution (0.1% povidone K30).
  • the sample was prepared by adding 100 mg of milled powder and 20 mL of dispersant to a 30 mL glass bottle. The particles were dispersed by agitation with a pipette, and then the capped bottle was placed in an ultrasonic water bath (Branson Ultrasonic bath, Model 5510-MT, output 135W, 42 Hz) such that the bath water level was half way up the side of the bottle. The sample was then sonicated for 30 minutes.
  • Branson Ultrasonic bath Model 5510-MT, output 135W, 42 Hz
  • the dispersed sample was added dropwise to the reservoir of the liquid sample handling unit until an obscuration value of approximately 7% was reached.
  • the internal sonic probe was run at 100% intensity for 300 seconds, and then the sample was circulated for 120 seconds before data collection. Data were collected at a beam angle setting of 65° when the obscuration value was between 5 and 10%. Each measurement was repeated in triplicate and the average of three measurements was reported. Particle size data from the milled powder are reported in Table 6.
  • the milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling.
  • the granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce lOOmg abiraterone acetate tablets having the composition shown in Table 7.
  • the dissolution rates of the tablets prepared as described above were measured in USP Apparatus II, 75 rpm in 900mL of pH 4.5 buffer with 0.1% SLS. Samples were analyzed by HPLC. Additionally, for comparison purposes, Zytiga® tablets were tested with the same dissolution conditions. Because Zytiga® tablets are 250mg which is approaching the solubility limit of the dissolution media, the tablets were cut to a weight equivalent to lOOmg of abiraterone acetate. Zytiga® samples were measured using UV at 270nm. The results of this analysis are shown in Table 8; full dissolution (>85% dissolved) of the prepared tablets was achieved in 5 minutes, wheras the Zytiga® tablets dissolution was achieved in 20 minutes.
  • Example 5 Phase I Study of 100, 200, and 400 mg Doses of Abiraterone Acetate
  • the abiraterone acetate 100 mg tablet formulation prepared as described in Example 4 was tested in healthy male patients under fasting conditions at lOOmg, 200mg, and 400mg doses (1, 2, or 4 x 100 mg tablets respectively).
  • a lOOOmg dose of Zytiga® was tested (4 x 250mg tablets). The results of this study are shown in Table 9.
  • Table 10 and Figures 3 A and 3B (diamonds, 5°C; squares, 25°C/60% RH; and triangles, 40°C/75% RH) provide an overview of the impurity levels in lots of milled DPI and tablets upon accelerated stability testing. Tablets stored refrigerated had an acceptably low level of impurities, but it is desirable to have formulation that can be stored under ambient conditions.
  • the impurity growth in the DPI and tablets containing fine particle abiraterone acetate is due to oxidative degradation of abiraterone acetate.
  • Aged Zytiga® (abiraterone acetate) tablets were tested for purity, and the impurity levels were found to be much lower than aged tablets containing fine particle abiraterone acetate.
  • the faster degradation in tablets containing fine particle abiraterone acetate could arise from a number of sources, including, but not limited to: greater surface area of the API, higher proportion of excipient relative to the API, and differences in excipients. Further studies found that the API has some degradation in the presence of the excipients, but the degradation is greatly accelerated once the mixture is milled. Data are provided in Table 11.
  • Dry milling of abiraterone acetate was carried out in the presence of lactose monohydrate and sodium lauryl sulfate and various antioxidants and/or sequestering agents.
  • the dry milling included a combination of ascorbic acid and fumaric acid or a combination of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT): the formulations are shown in Table 12.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • the two different DPI Formulations were used to prepare two different corresponding tablet Formulation as detailed in Table 13 by adding the indicated excipients to the DPI Formulations, dry granulating and tableting.
  • Table 13 Tablet Formulations Containing Antioxidant or Sequestering Agent
  • Table 14 contains data demonstrating that both tablet formulations with antioxidant had dramatically improved stability after 3 months storage at 40°C/75%RH compared to the formulation without antioxidant, with the BHA/BHT formulation nearly halting all degradation. This demonstrates that the addition of antioxidants and/or sequestering agents during milling can dramatically improve stability.
  • the dissolution rate of the abiraterone acetate in the Tablet Formulation Ascorbic/Fumaric and Tablet Formulation BHA/BHT was tested using USP Apparatus II at 75 rpm in 900 ml of pH 4.5 phosphate buffer with 0.1% SLS. Tablets for all three types of tablets had full dissolution (>85% of the abiraterone acetate dissolved) within 10 minutes.
  • An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT.
  • the composition of the material milled to form this intermediate is shown in Table 15.
  • the formulation was milled in a custom jacket-cooled 62 gallon attritor mill; the powder blend was milled with milling bodies for 72 minutes.
  • Table 15 Milled Drug Product Intermediate Containing BHA and BHT for Phase 1 clinical studies
  • the particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Two different methods were used to measure the particle size distributions, as described below:
  • Method 1 The dispersant used was an aqueous solution of 0.1% povidone 30. Approximately 20 mg of sample powder and 5 mL of dispersant was added to a plastic centrifuge tube. The tube was swirled to disperse the powder and then sonicated (Branson Digital Sonifier 250 with sonic probe model 102C) for 1 minute at 20% amplitude with a sonication cycle of 5 seconds on and 15 seconds off. The particle size analyzer sample dispersion unit was filled with the dispersant and the sample was pipetted into the reservoir until the target obscuration of 5-15% was reached and remained constant. The stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
  • sonicated Branson Digital Sonifier 250 with sonic probe model 102C
  • Method 2 The dispersant used was an aqueous solution comprising 0.1% of poloxamer 338 and 0.1% calcium chloride which was filtered through a 0.2 ⁇ nylon filter prior to use.
  • sample powder and 5 mL of dispersant solution was added to a glass vial.
  • the vial was capped and swirled to disperse the powder particles.
  • the vial cap was then loosened and the vial placed in the center of a sonic bath (Elma Elmsonic P30H ultrasonic bath).
  • the vial was immersed such that the bath liquid level was above the level of the dispersant in the vial, but the vial was not touching the bottom of the bath.
  • the sample was sonicated at 37kHz at 100% power for ten minutes.
  • the particle size analyzer sample dispersion unit was filled with dispersant and the sample was pipetted into the reservoir until an obscuration of 5-15% was obtained and remained constant.
  • the stirrer was run at 1500 rpm, and data were collected for 10 seconds. Three measurements were made and the average values of each particle size parameter were reported.
  • Table 16 presents a comparison of the particle size values for abiraterone acetate in the drug product intermediate (DPI) described in Table 15 before and after milling, using Methods 1 and 2 described above.
  • the milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling.
  • the granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 17.
  • Example 11 Phase I Study of 125, 500, and 625 mg Doses of Abiraterone Acetate Formulation Compared to Zytiga ® 1000 mg
  • the abiraterone acetate 125mg tablet formulation prepared as described in Example 10 was tested in healthy male patients under fasting conditions at 125mg, 500mg, and 625mg doses (1, 4, or 5 x 125 mg tablets respectively).
  • a lOOOmg dose of Zytiga® was tested (4 x 250mg tablets). The results of this study are shown in Table 19.
  • An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT. The composition of the material milled to form this intermediate is shown in Table 16. Two batches were milled with varying processing conditions, yielding slightly different particle size. Table 16: Additional Milled Drug Product Intermediate
  • the particle size distribution of the abiraterone acetate in both lots of drug product intermediate were measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 17.
  • the milled drug product intermediate from Batch 1 was combined with intragranular excipients and dry granulated using roller compaction and milling.
  • the granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce lOOmg abiraterone acetate tablets having the composition shown in Table 18.
  • An additional drug product intermediate formulation was prepared by dry milling abiraterone acetate, lactose monohydrate, sodium lauryl sulfate, BHA and BHT.
  • the composition of the material milled to form this intermediate is shown in Table 20.
  • the particle size distribution of the abiraterone acetate in this drug product intermediate was measured by light scattering using a Malvern Mastersizer 3000 model MAZ3000 particle size analyzer configured with a Hydro MV wet sample dispersion unit. Method 1 described in example 8 was utilized to obtain the particle size distribution shown in Table 21.
  • Table 21 Additional Particle Size Distribution Data for Abiraterone Acetate DPI Containing BHA and BHT
  • the milled drug product intermediate was combined with intragranular excipients and dry granulated using roller compaction and milling.
  • the granulation was blended with extragranular excipients and compressed in a rotary tablet press to produce 125mg abiraterone acetate tablets having the composition shown in Table 22.
  • Plasma samples were taken immediately prior to dosing and at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0, and 48.0 hours after administration of the test article. Samples were analyzed for abiraterone concentration, and the results were used to calculate pharmacokinetic parameters (AUCo - ⁇ , AUCo-t, and Cmax) for each subject and treatment.
  • the geometric mean values for AUCo-oo, AUCo-t, and Cmax when the test article was administered in the fed state were 1444.1 ng-h/mL, 1393.4 ng-h/mL, and 443.7 ng/mL respectively, while the geometric mean values for those same parameters were 322.7 ng-h/mL, 301.0 ng-h/mL, and 67.9 ng/mL when the drug was administered in the fasted state.
  • the ratios (fed/fasted) for AUCO-OD, AUCo-t, and Cmax were 4.48, 4.63, and 6.53, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
PCT/US2015/050889 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use WO2016044701A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EA201790650A EA201790650A1 (ru) 2014-09-18 2015-09-18 Лекарственная форма и способы применения абиратерона ацетата
MDA20170048A MD20170048A2 (ro) 2014-09-18 2015-09-18 Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
EP15842591.8A EP3193857A4 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use
TNP/2018/000318A TN2018000318A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.
AP2017009804A AP2017009804A0 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use
KR1020177008938A KR102491439B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법
BR112017003219A BR112017003219A2 (pt) 2014-09-18 2015-09-18 formulação de acetato de abiraterona e métodos de uso
KR1020237001893A KR102617537B1 (ko) 2014-09-18 2015-09-18 아비라테론 아세테이트 제제 및 사용 방법
MA40116A MA40116A1 (fr) 2015-05-08 2015-09-18 Formulation d'acétate d'abiratérone et ses procédés d'utilisation
CN201580050453.8A CN106687112A (zh) 2014-09-18 2015-09-18 醋酸阿比特龙制剂和使用方法
TN2017000098A TN2017000098A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.
SG11201701139YA SG11201701139YA (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use
CA2958316A CA2958316A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use
JP2017512783A JP2017528457A (ja) 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法
MX2017003525A MX2017003525A (es) 2014-09-18 2015-09-18 Formulacion de acetato de abiraterona y metodos de uso.
AU2015317466A AU2015317466A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use
IL250270A IL250270B (en) 2014-09-18 2017-01-25 Abiraterone acetate formulations and methods of use
PH12017500239A PH12017500239A1 (en) 2014-09-18 2017-02-09 Abiraterone acetate formulation and methods of use
CONC2017/0002472A CO2017002472A2 (es) 2014-09-18 2017-03-15 Formulación de acetato de abiraterona

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
US14/707,922 2015-05-08

Publications (1)

Publication Number Publication Date
WO2016044701A1 true WO2016044701A1 (en) 2016-03-24

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (enrdf_load_stackoverflow)
JP (1) JP2017528457A (enrdf_load_stackoverflow)
KR (2) KR102617537B1 (enrdf_load_stackoverflow)
CN (1) CN106687112A (enrdf_load_stackoverflow)
AP (1) AP2017009804A0 (enrdf_load_stackoverflow)
AU (1) AU2015317466A1 (enrdf_load_stackoverflow)
BR (1) BR112017003219A2 (enrdf_load_stackoverflow)
CA (1) CA2958316A1 (enrdf_load_stackoverflow)
CO (1) CO2017002472A2 (enrdf_load_stackoverflow)
EA (1) EA201790650A1 (enrdf_load_stackoverflow)
IL (1) IL250270B (enrdf_load_stackoverflow)
MD (1) MD20170048A2 (enrdf_load_stackoverflow)
MX (1) MX2017003525A (enrdf_load_stackoverflow)
PH (1) PH12017500239A1 (enrdf_load_stackoverflow)
SG (1) SG11201701139YA (enrdf_load_stackoverflow)
TN (2) TN2017000098A1 (enrdf_load_stackoverflow)
WO (1) WO2016044701A1 (enrdf_load_stackoverflow)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
EP3606506A4 (en) * 2017-04-07 2021-01-06 MAA Laboratories, Inc. PROCESSES FOR IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS
WO2021184611A1 (zh) * 2020-03-14 2021-09-23 山东新时代药业有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
KR20220166856A (ko) * 2020-04-16 2022-12-19 타반타 테라퓨틱스 헝가리 인코포레이티드 전립선암을 치료하기 위한 방법 및 조성물
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141013B2 (ja) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド 商業的規模での封入ナノ粒子の製造
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet.", CLNCALTRALS.GOV., 2013, pages 1 - 3, XP055419461, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT01640093?term=zytiga&rank=3> [retrieved on 20151103] *
See also references of EP3193857A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US11311493B2 (en) 2017-04-07 2022-04-26 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
US12268786B2 (en) 2017-04-07 2025-04-08 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
EP3606506A4 (en) * 2017-04-07 2021-01-06 MAA Laboratories, Inc. PROCESSES FOR IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTS
AU2018249608B2 (en) * 2017-04-07 2024-05-02 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
US11559534B2 (en) 2019-03-06 2023-01-24 Propella Therapeutics, Inc. Abiraterone prodrugs
US12138273B2 (en) 2019-03-06 2024-11-12 Propella Therapeutics, Inc. Abiraterone prodrugs
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
WO2021184611A1 (zh) * 2020-03-14 2021-09-23 山东新时代药业有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
CN115515583A (zh) * 2020-05-08 2022-12-23 詹森药业有限公司 醋酸阿比特龙和尼拉帕尼的药物配制品
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Also Published As

Publication number Publication date
KR20230014878A (ko) 2023-01-30
TN2017000098A1 (en) 2018-10-19
KR20170070025A (ko) 2017-06-21
KR102617537B1 (ko) 2023-12-22
IL250270A0 (en) 2017-03-30
JP2017528457A (ja) 2017-09-28
IL250270B (en) 2021-02-28
CO2017002472A2 (es) 2017-07-11
EP3193857A4 (en) 2018-04-11
MX2017003525A (es) 2017-06-21
BR112017003219A2 (pt) 2017-11-28
CA2958316A1 (en) 2016-03-24
AP2017009804A0 (en) 2017-03-31
AU2015317466A1 (en) 2017-02-23
PH12017500239A1 (en) 2017-07-03
SG11201701139YA (en) 2017-03-30
MD20170048A2 (ro) 2017-08-31
EA201790650A1 (ru) 2017-07-31
CN106687112A (zh) 2017-05-17
KR102491439B1 (ko) 2023-01-25
EP3193857A1 (en) 2017-07-26
TN2018000318A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2018241103B2 (en) Abiraterone Acetate Formulation
US9889144B2 (en) Abiraterone acetate formulation and methods of use
KR102491439B1 (ko) 아비라테론 아세테이트 제제 및 사용 방법
US10292990B2 (en) Abiraterone steroid formulation
HK40018807A (en) Abiraterone acetate formulation
HK40018807B (en) Abiraterone acetate formulation
OA18485A (en) Abiraterone acetate formulation and methods of use.
OA18169A (en) Abiraterone acetate formulation
HK1220162B (en) Abiraterone acetate formulation
HK1234990A1 (en) Abiraterone acetate formulation and methods of use
HK40020084A (zh) 乙酸阿比特龙酯制剂
HK40020084B (zh) 乙酸阿比特龙酯制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15842591

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 250270

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12017500239

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2958316

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015317466

Country of ref document: AU

Date of ref document: 20150918

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017003219

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017512783

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2017000127

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: NC2017/0002472

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/003525

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 40116

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 20177008938

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201703661

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201790650

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20170048

Country of ref document: MD

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015842591

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112017003219

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170217